Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × regorafenib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 7 Squamous Cell Carcinoma of Head and Neck 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Astrocytoma 2 Wilms Tumor 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Neuroblastoma 1 Neoplasms 1 Meningioma 1 Melanoma 1 Hepatoblastoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1

Interventions

Temozolomide 22 Bevacizumab 18 Cyclophosphamide 7 Lomustine 6 Irinotecan 6 Carboplatin 6 3-Iodobenzylguanidine 6 Topotecan 5 Radiotherapy 5 Radiosurgery 4 Nivolumab 4 Filgrastim 4 Everolimus 4 fludarabine phosphate 3 Vincristine 3 Sirolimus 3 IL13-PE38 3 Etoposide 3 Drug Therapy 3 Busulfan 3 Antilymphocyte Serum 3 thymoglobulin 2 sonidegib 2 ribociclib 2 pembrolizumab 2 paclitaxel-Angiopep-2 conjugate 2 olaparib 2 fluorodopa F 18 2 fludarabine 2 etoposide phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970447 2025-09-09

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡